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Abstract
Background: The estrogen receptor alpha (ERa) is found predominately in the nucleus, both in hormone
stimulated and untreated cells. Intracellular distribution of the ERa changes in the presence of agonists but the
impact of different antiestrogens on the fate of ERa is a matter of debate.
Results: A MCF-7 cell line stably expressing GFP-tagged human ERa (SK19 cell line) was created to examine the
localization of ligand-bound GFP-ERa. We combined digitonin-based cell fractionation analyses with fluorescence
and immuno-electron microscopy to determine the intracellular distribution of ligand-bound ERa and/or GFP-ERa.
Using fluorescence- and electron microscopy we demonstrate that both endogenous ERa and GFP-ERa form
numerous nuclear focal accumulations upon addition of agonist, 17b-estradiol (E2), and pure antagonists (selective
estrogen regulator disruptor; SERD), ICI 182,780 or RU58,668, while in the presence of partial antagonists (selective
estrogen regulator modulator; SERM), 4-hydroxytamoxifen (OHT) or RU39,411, diffuse nuclear staining persisted.
Digitonin based cell fractionation analyses confirmed that endogenous ERa and GFP-ERa predominantly reside in
the nuclear fraction. Overall ERa protein levels were reduced after estradiol treatment. In the presence of SERMs
ERa was stabilized in the nuclear soluble fraction, while in the presence of SERDs protein levels decreased drasti-
cally and the remaining ERa was largely found in a nuclear insoluble fraction. mRNA levels of ESR1 were reduced
compared to untreated cells in the presence of all ligands tested, including E2. E2 and SERDs induced ERa degra-
dation occurred in distinct nuclear foci composed of ERa and the proteasome providing a simple explanation for
ERa sequestration in the nucleus.
Conclusions: Our results indicate that chemical structure of ligands directly affect the nuclear fate and protein
turnover of the estrogen receptor alpha independently of their impact on transcription. These findings provide a
molecular basis for the selection of antiestrogen compounds issue from pharmacological studies aimed at
improving treatment of breast cancer.
Background
The estrogen receptor alpha (ERa) is a member of the
steroid nuclear receptor family. The gene coding for
ERa (ESR1) is regulated by seven different promoters
that yield different transcripts, making it one of the
most complex genes in the human genome [1]. Several
splice variants have been described for estrogen receptor
a, but whether all these variants are expressed as
functional proteins with biological functions is not
clear [2,3]. In the classic pathway ERa undergoes a
conformational change in the presence of estradiol,
which leads to association with ERa target genes via
direct binding to regulatory elements and modulation of
their expression. This basic mechanism is influenced by
other regulatory factors including alternate receptor iso-
forms, and the stoichiometry of coactivator and core-
pressor proteins. Coactivators have a common LXXLL
motif [4] and after binding to the AF-2 domain of ERa,
facilitate recruitment of other factors [5]. Mutation ana-
lysis combined with crystallographic studies demon-
strated that receptor-coactivator interactions are
mediated through the ERa helix12 and the LXXLL
motif of coactivators [6]. 4-hydroxytamoxifen (OHT)
acts by blocking AF-2 activity so it is an antagonist in
cells where AF-2 is dominant and a partial agonist
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where AF-1 is dominant [7]. Fulvestrant/ICI 182,780
(ICI) is known to block both, AF-2 and AF-1 activities.
Estrogens have a proliferative effect on various tissues,
including the breast. Thus ERa plays a key role in mam-
mary tumour development. In mammary cells, the
effects of 17b-estradiol (E2) can be antagonized by com-
pounds such as OHT, a tamoxifen metabolite that is a
selective estrogen receptor modulator (SERM), and ICI,
a selective estrogen receptor disruptor (SERD). OHT
has partial agonist activity, depending on the tissue and
response examined while ICI compounds are totally
devoid of agonist activity in the models studied to date
[8-10]. ERa-OHT complexes accumulate in nuclei and
ICI treatment provokes rapid degradation of the ERa-
ICI complex by the nuclear proteasome [11,12].
Intracellular levels of ERa are downregulated in the
presence of E2, its cognate ligand, through the ubiqui-
tin/proteasome (Ub/26S) pathway [10]. Polyubiquitina-
tion of liganded ERa is catalyzed by at least three
enzymes: the ubiquitine-activating enzyme E1 activated
ubiquitin is conjugated by E2 with lysine residues
through an isopeptide bond by the E3 ubiquitin ligase.
Polyubiquitinated ERa is then directed to the protea-
some for degradation [13,14]. Most known ubiquitin
attachment sites reside within the C-terminus of the
ERa. Berry et al. recently also identified two receptor
lysines, K302 and K303 in the hinge region of ERa
which are involved in E2 mediated and ICI induced
ERa degradation in breast cancer cells [15]. Although
ER-dependent transcription regulation and protea-
some-mediated degradation of the ERa are linked [16],
transcription per se is not required for ERa degrada-
tion and assembly of the transcription-initiation com-
plex is sufficient to target ERa for degradation by the
nuclear fraction of the proteasome [13]. Using immu-
nocytochemical studies it was shown that ERa resides
predominantly in the nucleus both in presence or
absence of hormone [17]. Maruvada et al. [18] deter-
mined that a small proportion of transiently trans-
fected GFP- ERa exists in the cytoplasm in the
absence of hormone. They proposed that unbound
ERa shuttles between the cytoplasm and nucleus in
living cells. Estradiol and E2 antagonists affect ERa
protein turnover rates and modulate transcription of
ERa target genes [19,20]. It has been shown that E2
induced degradation of ERa is necessary for its ability
to rapidly activate transcription [21]. Interestingly, two
chemically different SERDs (ICI and RU58,668) compe-
titively inhibit estradiol-mediated activation by ERa
and induce rapid down-regulation of the receptor
[22,23]. In contrast, in the presence of tamoxifen ERa
protein levels increase, although the effect of OHT on
transcription is similar to the one observed for SERD’s
in MCF-7 cells [19].
In the present study we determine the impact of dif-
ferent ligands on nucleocytoplasmic shuttling of ERa
and examine the relationship between localization and
proteolysis, two mechanisms involved in ERa-mediated
regulation in MCF-7 cells. To achieve this goal, we
determined ERa protein concentration, subnuclear loca-
lization of ERa with relationship to the proteasome, and
the level of ESR1 transcription upon treatment with var-
ious antiestrogens.
Results
Ligands regulate ERa protein levels and transcription
rates independently
We first examined the kinetics of ERa protein turnover
in MCF-7 cells following treatment with estradiol (E2),
two SERMs (4-hydroxytamoxifen or OHT and
RU39,411 or RU39) and two SERDs (ICI 182,780 or ICI
and RU58,668 or RU58). It has been proposed that
ligand dependent ERa regulation may result from the
presence a long aliphatic side chain on steroid core.
Thus in this study we selected RU39 and RU58 which
are derivatives of 17b-estradiol but with different side
chains. RU39 has a dimethyl-amino-ethoxy-phenyl side
chain similar to the one in tamoxifen, while RU58 has a
bulky hydrophobic side chain similar to the one in Ful-
vestrant (ICI) (Figure 1A). ERa protein levels in E2, ICI
and RU58 treated MCF-7 cells rapidly decreased (Figure
1B). Time course experiments showed that 1 h after E2
induction, the detected amount of ERa protein
accounted for only 40% of ERa levels before treatment;
after 4 h, ERa levels were as low as 20% of the quantity
of ERa present in untreated cells, and after 16 h ERa
protein remained at a level equivalent to the one
observed 1 h after addition of E2. Treatment with
SERDs (ICI and RU58) resulted in >70% reduction of
ERa protein levels after 1 h, 4 h and even 16 h reaching
95% after 1 h exposure to ICI (Figure 1B). Treatment of
MCF-7 cells with OHT or RU39 (Figure 1B), two com-
pounds classified as SERM, reduced from 40% to 50% of
ERa protein levels at the initial 1 h time-point and
about 20% after 16 h and 4 h treatment with OHT and
RU39, respectively. In addition, ERa protein levels were
almost equivalent to the ones detected in untreated cells
after 4 h or 16 h culture in the presence of OHT or
RU39. Hence, ERa protein levels are stabilized by
SERMs.
To assess whether changes in protein levels reflect
variations of ERa protein stability or of transcription
rates of the ESR1 gene, we quantified ERa mRNA accu-
mulated following 16 h treatment with the different
compounds (Figure 1C). ESR1 mRNA expression was
greatly reduced after treatment with ERa ligands. In the
presence of E2, only 40% of ESR1 mRNA could be
recovered. Similarly, treatment with SERMs and SERDs
Kocanova et al. BMC Cell Biology 2010, 11:98
http://www.biomedcentral.com/1471-2121/11/98
Page 2 of 13
repressed ESR1 mRNA transcription by 45%-60% rela-
tive to untreated MCF-7 cells. Despite the fact that a
reduction in ERa protein levels was readily detectable
after 1 h and significant after 16 h (Figure 1B), we
observed that E2 induced a 7 to 10 fold increase in
mRNA levels of the ERa-target gene GREB1 compared
to mock treated cells (Figure 1C). GREB1 transcription
was inhibited by SERMs and SERDs (> 40% reduction
compared to untreated cells; Figure 1C). These results
were expected since E2 is known to activate this ERa
target gene, while SERMs and SERDs are antiestrogens
and thus repress GREB1 transcription in ERa positive
mammary tumour cells [20].
Thus, in MCF-7 cells, variations in ERa protein levels
do not necessarily correlate with ESR1 transcription in
the presence of ligands. We note that the decrease in
ERa protein levels is more pronounced after treatment
with SERDs than after addition of E2, while the effect of
hormone and SERDs on ESR1 mRNA accumulation was
comparable. These results indicate that reduction of
ERa protein levels following treatment with SERDs can-
not be solely attributed to decreased ESR1 mRNA levels.
SERDs apparently act both on transcription of the ESR1
gene and on ERa protein turnover. In contrast, ERa
protein levels appear stable after 16 h treatment with
SERMs (data not shown) despite reduced ESR1 expres-
sion levels. This suggests that binding to SERMs stabi-
lizes the ERa.
Ligands directly affect intracellular distribution and
stability of ERa
SERMs and SERDs can be distinguished based on mole-
cular mechanisms [9]. To unambiguously determine









































































































Figure 1 Protein and mRNA levels of ligand bound ERa in MCF-7 cells. A) Chemical structure of 17b-estradiol, SERMs (OHT, RU39) and
SERDs (ICI, RU58). B) Western blot and quantification of ERa protein levels after 1 h, 4 h and 16 h treatment with 10 nM E2, 1 μM ICI, 1 μM
RU58, 1 μM OHT and 1 μM RU39 relative to ERa protein levels in untreated (EtOH) MCF-7 cells. 2 μg of total protein were loaded. Relative
protein levels from three independent experiments were quantified. C) Total RNA was extracted from MCF-7 cells treated or not for 16 h with 10
nM E2 or anti-estrogens. Relative expression level of the ESR1 and GREB1 genes was analyzed by qRT-PCR. TBP served as an internal control (see
Methods). Data shown are an average of three independent experiments, error bars represent ± S.E. mean.
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trafficking in response to treatment with various ligands
we established a MCF-7 cell line stably expressing GFP-
ERa from a CMV promoter. It was previously shown
that transiently expressed GFP-ERa is functional using
an estrogen response element driven luciferase reporter
gene [24]. Expression of GFP-ERa in MCF-7 cells did
reportedly not alter cell cycle progression and GFP-ERa
participated in estrogen target gene regulation similarly
to endogenous ERa [25]. We tagged the N-terminus of
the human ERa with the S65T variant of GFP for trans-
fection and stable integration in MCF-7 cells. Several
clones were recovered and screened for total GFP-ERa
protein content after treatment with E2, OHT or ICI
using fluorescence microscopy and western blots. Here,
we selected a MCF-7 derived clone (SK19) expressing
GFP-ERa in which changes in endogenous ERa protein
levels in response to a 4 h treatment with E2, OHT and
ICI were identical to the ones observed in MCF-7 cells
(compare lanes labeled ERa in MCF-7 and SK19 cells in
Figure 2A). In addition, mRNA expression levels of
some ERa target genes, ESR1, TFF1/pS2, GREB1 and
PGR, were verified in the selected clone SK19 and
compared to gene expression levels in MCF-7 cells
(Figure 2B). mRNA levels of the progesterone receptor
gene (PGR) and GREB1 increased rapidly after addition
of 10 nM E2 to cells grown in steroid free medium to
reach 2.2 to 2.8 fold (after 2 h) for both genes, and after
16 h to reach from 3.8 to 4.6 fold for PGR and 6.3 to 7.0
fold for GREB1 gene, in MCF-7 and SK19 cells respec-
tively. TFF1 mRNA also accumulated after 16 h E2 treat-
ment to reach 1.5 fold in both cell lines. As expected,
ESR1 transcription was reduced in the presence of E2.
The RPLPO gene is not a target of ERa and its expression
levels were insensitive to hormone addition. Expression
levels of all tested genes were similar in SK19 and MCF-7
cells. Thus the presence of GFP-ERa does not alter hor-
mone-responsiveness at the transcriptional level.
In SK19 cells, GFP-ERa protein accounted for 50% of
total ERa (GFP-ERa and endogenous ERa) in untreated
cells. In the presence of E2 both GFP-ERa and endo-
genous ERa protein levels are reduced (Figure 2A). The
CMV promoter being insensitive to E2 and antiestro-
gens, GFP-ERa protein levels are unlikely to be tran-
scriptionally regulated. This observation together with
the results shown in Figure 1 provides evidence that
ERa protein turnover is regulated directly by binding of
the receptor to ligands and its subsequent degradation.
Previous studies have demonstrated that GFP-ERa
resides predominantly in the nucleus in transiently trans-
fected mammary tumour cell lines [24], Hela cells [26,27]
and in MCF-7 cells expressing GFP-ERa from an induci-
ble promoter [25]. These microscopy based observations
largely contradict results based on cellular fractionation
which suggest that large amounts of ERa, in the absence
or the presence of ligands, associate with the cytoplasmic
fraction [19]. It has been proposed that the relative
amount of cytoplasmic ERa is indicative of the mechan-
ism of action of certain antiestrogens [19]. Commonly
used cell fractionation protocols include a detergent
based extraction step. Importantly, ERa and other
nuclear receptors such as the glucocorticoid receptor
(GR) are easily extracted from the nucleus in the pre-
sence of low concentrations of detergents such as NP40
(V. Marsaud and H. Richard-Foy, unpublished observa-
tions). As a consequence, apparent enrichment of ERa or
GR in the cytoplasm likely results from the extraction
protocol rather than a specific behavior of nuclear recep-
tors. Here, we used a digitonin based cell fractionation
protocol to determine the distribution of unbound and
ligand-bound ERa and GFP-ERa in different cellular
compartments (Figure 2C). Effectiveness of the fractiona-
tion protocol (for details see Methods) was confirmed
using lamin A for the nuclear insoluble fractions, cyto-
keratin 18 for the nuclear and cytoplasmic fractions, and
a-tubulin for the cytoplasmic fraction (Figure 2C). Treat-
ment of cells with E2 and various antiestrogens did not
affect cellular distribution of these proteins. We found
that endogenous ERa associates predominantly with the
nuclear fraction in the SK19 cells. In untreated cells, the
part of ERa retained in the cytoplasm corresponded to
~20% of total endogenous ERa detected using the HC-20
antibody (Figure 2C, lanes 1 and 13). Similarly, the bulk
of GFP-ERa, detected using either the HC-20 antibody
or an antibody directed against GFP, was found in the
nucleus. Following addition of E2, we note an overall
decrease in ERa protein levels that could mainly be
attributed to a reduction in nuclear ERa (Figure 2C,
lanes 4-6). Treatment of SK19 cells with SERDs, ICI or
RU58 leads to a decrease in overall ERa protein levels as
shown for MCF-7 cells in Figure 1B. Notably, the remain-
ing ERa was concentrated in the nuclear insoluble frac-
tion which corresponded to ≥40% of total ERa in the
presence of either ICI or RU58 (Figure 2C, lanes 12 and
21) suggesting that the nuclear soluble fraction was
rapidly degraded. In contrast, we found that treatment
with OHT and RU39 (Figure 2C, lanes 7-9 and 16-18)
resulted in a cellular distribution similar to the one
observed in untreated cells (Figure 2C, lanes 1-3) where
at least 50% of ERa protein remained in a soluble
nuclear compartment. Our cellular fractionation proto-
col is robust since the effects of various ligands are
reproducible inside each category: OHT and RU39
induce the same effect on ERa protein distribution and
this effect is distinct from the one of ICI and RU58. In
addition, we show that occupation of different cellular
compartments by GFP-ERa reflected the localization of
endogenous ERa as detected by fluorescence imaging
(see below).
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Ligands induce specific intracellular relocalization of
GFP-ERa
GFP-ERa can be visualized in SK19 cells using conven-
tional wide-field microscopy. SK19 cells were cultured
on conventional glass microscopy coverslips in phenol-
red free media for 3 days. Culture conditions were
identical to conditions used for cell fractionation, immu-
noblotting or RNA extraction prior to RT-qPCR. Figure
3A shows representative images of SK19 cells treated or
not with E2, SERMs and SERDs. We note that in the
SK19 cell line GFP-ERa was excluded from the nucleoli,
as previously observed for the cellular distribution of
endogenous ERa in MCF-7 cells [28,29] and of
transiently transfected GFP-ERa [24,26,30], under all
conditions tested. Exposure times were identical for all
conditions examined by fluorescence microscopy.
In untreated cells, ERa was uniformly distributed in
the nucleus (compare GFP-ERa fluorescence (Figure
3Ab), to the DAPI (4’,6-diamidino-2-phenylindole)
nuclear stain in Figure 3Aa). A linear scan across the
entire field including cytoplasm and nucleus (Figure
3Ac) shows that the cytoplasmic GFP-ERa fluorescence
was barely above background (~15% of the maximum
fluorescence intensity detected in the nucleus) which
correlates with observations from cell fractionation
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Figure 2 Nuclear accumulation and degradation of the estrogen receptor alpha in MCF7 and SK19 cells. A) Protein levels of endogenous
ERa and GFP-ERa in MCF-7 and SK19 cells in response to E2 and to anti-estrogens. The SK19 cell line was generated from MCF-7 cells by stably
transfecting a GFP-ERa expression vector (pEGFP-C2-hERa). B) Total RNA was extracted from SK19 and MCF-7 cells treated or not for 2 h and 16
h with 10 nM E2. Relative expression level of the ESR1, TFF1, GREB1 and PGR genes in SK19 cells was analyzed by qRT-PCR and compared to
gene-expression regulation in MCF-7 cells. RPLP0 served as an internal control (see Methods). Data shown are an average of two independent
experiments, error bars represent ± S.E. mean. C) Cellular distribution of ERa and GFP-ERa from digitonin based cellular fractionation
experiments. SK19 cells were treated with drugs for 3 h. Nuclear fractions of untreated and treated cells with 10 nM E2, 1 μM OHT, 1 μM ICI, 1
μM RU39 and 1 μM RU58, were isolated as described in “Methods”. Nuclear content of ERa and GFP-ERa was analyzed by Western Blotting
using anti-ERa antibodies. The specific subcellular proteins, a-tubulin for cytoplasmic fraction (Cyt), Lamin A for nuclear insoluble fraction (NI)
and cytokeratin 18 for nuclear soluble fraction (NS) are loading controls for the different cellular compartments. Results shown are representative
of at least 3 independent experiments.
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Figure 3 Estrogen, SERDs and SERMs induce distinct intracellular behavior of ERa. A) SK19 cells were incubated for 1 h with E2 and
different anti-estrogens (SERDs or SERMs), fixed, stained with DAPI and examined by fluorescence microscopy using an Olympus IX-81 inverted
microscope. GFP-ERa forms intranuclear foci in the presence of 10 nM E2, 1 μM RU58 and 1 μM ICI, but remains uniformly distributed in the
nucleus after addition of 1 μM OHT and 1 μM RU39. Linescans indicate relative fluorescence intensities in the cytoplasm and the nucleus in the
cells imaged using identical parameters. Pictures are representative of at least three independent experiments. Bar, 5 μm. B) Representative
electron micrograph of MCF-7 cells treated with 1 μM ICI for 1 h. Inset indicates formation of ERa clusters in the nucleus after ICI addition. Bar,
2 μm and 500 nm.
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GFP-ERa rapidly relocalized to accumulate in numerous
foci scattered throughout the nucleoplasm (Figure 3Ae).
In E2 treated cells, no GFP-ERa fluorescence could be
detected in the cytoplasm (see linescan Figure 3Af). In
contrast, after 1 h treatment with SERMs, OHT or
RU39, we did not observe any intranuclear reorganiza-
tion of GFP-ERa compared to untreated cells. This
observation also correlates with our fractionation experi-
ments (Figure 2C, lanes 1-3 compare to lanes 7-8 and
16-18). GFP-ERa staining remained diffuse with fluores-
cence intensity comparable to mock cells (Figure 3A b,
n, r and corresponding linescans Figure 3A c, o, s).
However, again no cytoplasmic GFP-ERa could be
detected.
The distribution of the intensity of the fluorescent sig-
nals was determined within nuclei excluding the nucleo-
lus. The frequency of pixels with respect to their
intensity allows to calculate a coefficient of variation
(CV). In cells treated with SERMs the CV was compar-
able to the one in control cells while the CV was 2 to 3
fold higher in cells exposed to E2 or SERDs (Table 1).
This quantitive measure strengthens our observation
that ERa accumulates in intranuclear foci when bound
to E2 or SERDs but not in the presence of SERMs.
Upon exposure to SERDs, both ICI and RU58, GFP-
ERa accumulated at numerous sites, reminiscent of the
ones observed in the presence of E2 (Figure 3A h, k and
3Ae). We ascertained that the fluorescent foci detected
in SK19 cells correspond to an accumulation of endoge-
neous ERa using immuno-electron microscopy of MCF-
7 cells. Several immunogold labeled ERa molecules
were frequently detected within ~100 nm distance from
each other in 80 nm thin sections of E2 or ICI treated
cells (Figure 3B).
In addition, in SK19 cells, the maximum fluorescence
intensity measured after E2 and ICI treatments
decreased by 20-40% as compared to untreated cells
consistent with degradation of GFP-ERa (Figure 3Af
and 3Ai compare to 3Ac). The effects of ICI and RU58
were indistinguishable suggesting that both molecules
operate via similar molecular mechanisms despite signif-
icant structural differences [19].
Proteasome-dependent degradation of ERa bound to E2
or SERDs
ERa is a short-lived protein (half-life of >3 h for
unbound ERa and ~ 1-3 h for ligand-bound ERa)
[10,31]. ERa degradation occurs in presence of natural
ligands (E2) or pure antiestrogens such as ICI in a pro-
teasome dependent manner [13,14,32].
The 26S proteasome is a large protein complex (1500-
2000 kDa) present in the cytoplasm and nucleus of
eukaryotic cells. The catalytic core of this multi-subunit
complex, described as the 20S proteasome, contains a
and b subunits [33]. We visualized GFP-ERa and the
20S proteasome subunit a2 in SK19 cells. SK19 cells
grown on glass coverslips and treated as described were
fixed, permeabilized and subjected to indirect immuno-
fluorescence using a monoclonal anti-20S proteasome
subunit a2 primary antibody. Images acquired on an
Olympus inverted wide-field microscope in 3 D and
subjected to deconvolution revealed punctuate nuclear
staining of proteasome subunits throughout the nucleus
(Figure 4A and 4D, center panels). We did not observe
any cytoplasmic staining of this proteasome subunit
under our culture conditions. In the presence of E2,
GFP-ERa accumulated at numerous nuclear sites that
colocalized at least partially with proteasome foci
(Figure 4A panel f).
Next we used a double-immuno-nanogold labelling
approach in MCF-7 cells to characterize the extent of
ER/a2 colocalization. Upon exposure to E2, at least four
nuclear clusters per nuclear sections were detected. In
the majority of clusters more than 3 gold particles for
each protein were present (as indicated by circles in
Figure 4B). Endogenous ERa (represented by 10 nm
gold particles) colocalized with the 20S proteasome sub-
unit a2 (represented by 6 nm gold particles) in nuclear
microdomains of about 100 nm in diameter (Figure 4B,
inset).
We then determined the effect of LMB (Leptomycin
B), an inhibitor of the nuclear export receptor CRM1,
and of ALLN (acetyl-leucyl-leucyl-norleucinal), an inhi-
bitor of the proteasome, on SERD-dependent degrada-
tion of ERa in SK19 cells. SK19 cells were pretreated
with 10 nM LMB or 100 μM ALLN for 30 min. Figure
4C shows that LMB did not block E2, ICI or RU58
induced ERa degradation suggesting that SERD-bound
ERa is degraded in the nucleus. In the presence of E2,
but not ICI or RU58, degradation was slightly less pro-
nounced in cells pretreated with LMB suggesting that a
fraction of E2 bound ERa is also degraded by the cyto-
plasmic proteasome. Furthermore, ALLN inhibited E2,
ICI and RU58 induced degradation of ERa confirming
that SERD-ERa complexes were degraded by the
nuclear proteasome (Figure 4C, lanes 6, 9 and 12). Note
that at the protein level, GFP-ERa is degraded to a
Table 1 Mean coefficient of variation and its standard



















Coefficients of variation of fluorescent intensities were measured after
treatment with 10 nM E2 and anti-estrogens as described in Methods. The
distribution of the intensity of the fluorescent signals was determined within
nuclei excluding the nucleolus in MCF-7 cells (n = 15 - 20 cells).
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lesser extent than endogenous ERa which is likely to be
a consequence of reduced transcription of ESR1 in the
presence of E2 and SERDs. GFP-ERa transcription is
under the control of a CMV promoter which insensitive
to antiestrogens.
Finally, we investigated the distribution of GFP-ERa
and the 20S proteasome subunit a2 in SK19 cells trea-
ted with ICI or RU58 (Figure 4D). GFP-ERa foci also
significantly overlapped with accumulation sites of the
20S proteasome subunit a2 throughout the nucleus
(Figure 4D, insets of panels c and i). On average we
observed larger and more frequent GFP-ERa-protea-
some complexes in the presence of SERDs than in the
presence of E2 consistent with the fact that ERa is
readily degraded when ERa is bound to SERDs. As a
consequence of the ALLN treatment, contacts between
GFP-ERa and proteasome foci were largely abolished
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Figure 4 Nuclear Proteasome-GFP-ERa contacts are frequent in the presence of E2 and SERDs. A) SK19 cells treated for 3 h with drugs as
described in Methods. Cells were fixed and subjected to immunofluorescence using a monoclonal anti-20S proteasome subunit a2 primary
antibody, followed by incubation with the Alexa Fluor® 647 goat anti-mouse secondary antibody. Right panels represent colocalization of GFP-ERa
and 20S proteasome (insets): untreated cells (4A,c) and 10nM E2 treated cells (4A,f),. Images are representative of three independent experiments.
Bar, 5 μm. B) 80 nm thin sections of MCF-7 cells were incubated with anti-ERa and anti-20S proteasome subunit a2 antibodies. Secondary
antibodies coupled with 10 nm and 6 nm gold particles were used against anti-ERa (white arrowhead) and anti-20S proteasome (black arrowhead),
respectively. Grids were then processed for electron microscopy. Colocalization of both proteins is indicated by circles. Bar, 500 nm. The area of
selected electron micrograph shows colocalization clusters where at least 3 gold particles for each protein are present (inset). Bar, 100 nm. C)
Western blot showing SERD-mediated degradation of ERa through the nuclear proteasome. SK19 cells were pre-treated or not with inhibitor of
nuclear export (10 nM LMB) or proteasome inhibitor (100 μM ALLN) for 30 min and then treated with vehicle (EtOH as reference), 10 nM E2, 1 μM
ICI, or 1 μM RU58 for 3 h. ERa and GAPDH (internal control) detection by Western blotting shows proteasome-dependent degradation of ERa
upon E2 and SERDs stimulation. D) SK19 cells treated for 3 h with SERDs were pre-treated or not with proteasome inhibitor ALLN (details see in
Methods). Right panels represent colocalization of GFP-EPa and 20S proteasome subunit a2 (insets): SERDs pre-treated cells without (4Dc and i) or
with (4Df and l) 100 μM ALLN. Images are representative of three independent experiments. Bar, 5 μm.
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Interestingly, in a few cells treated with either E2 or
SERDs we observed a single very large site of accumula-
tion of the 20S proteasome a2 subunit (data not
shown). These sites, also called clastosomes, were
reported to colocalize with the c-jun and c-fos proteins
[34], very unstable proteins with half lives of less than
90 min. In our cells, clastosomes did not colocalize with
GFP-ERa foci which may indicate that E2 bound ERa is
more stable than c-jun and/or c-fos proteins.
Discussion
The available quantity of ERa is a limiting factor in the
response to ligands, estrogen and antiestrogens. Thus,
determination of ERa cell content in patients is not
only the first parameter for tumour classification, but
also a powerful tool to predict response to hormone-
therapies. ERa protein levels vary under physiological
states, during tumor progression, and beyond therapy
[10,35,36]. ERa protein levels are tightly regulated by
the ubiquitin-proteasome pathway and loss of this con-
trol is associated with hormone insensitivity in breast
cancer [37].
Most members of the nuclear receptor superfamily
form focal accumulations within the nucleus in response
to hormone [38]. Receptors undergo constant exchange
between target sequences, multi-protein complexes
including a variety of transcription factors, as well as
subnuclear structures that are as yet poorly defined. The
estrogen receptor alpha is found almost exclusively in
the nucleus, both in hormone stimulated and untreated
cells which makes it an exception among nuclear recep-
tors which generally translocate from the cytoplasm into
the nucleus upon hormone stimulation. Hager and col-
leagues [38] proposed that distribution of the ERa is
dependent not only on localization signals, but also on
the nature and composition of the associated macromo-
lecular complexes. Formation of these complexes
depends on the nature of the ligand bound to ERa.
Thus, as demonstrated here, ligands directly affect the
nuclear fate of the receptor.
We created a MCF-7 cell line stably expressing GFP-
tagged human ERa to levels equivalent to endogenous
ERa, to determine the localization of ligand-bound
GFP-ERa in mammary tumor cells. We demonstrate
that few hours after treatment cellular localization of
the ERa correlates with the nature of the ligand inde-
pendently of its impact on transcription.
In the presence of E2 and SERMs which induce bind-
ing of ERa to target sequences and subsequent forma-
tion of macromolecular complexes, the small
cytoplasmic fraction of E2 bound ERa rapidly translo-
cated into the nucleus suggesting that DNA binding
attracts cytoplasmic ERa. In contrast, SERD bound cyto-
plasmic ERa was retained in the cytoplasm. SERDs
induce a conformational change of ERa independently
of its localization (cytoplasmic or nuclear) which leads
to its rapid degradation. Our data also corroborate
recent observations by Long and co-workers [39,40] that
ICI induces specific nuclear matrix interaction of pro-
tein-ERa complexes with cytokeratins 8 and 18 which
mediate immobilization and turnover of ERa. A non
direct role of ERa in the cytoplasm has been proposed
to play a role in acquired resistance to antiestrogens, in
particular OHT [41]. Indeed, in OHT resistant cells, the
ERa accumulated in the cytoplasm, suggesting that
SERM stimulated ERa relocalization into the nucleus
may be necessary for anti-hormone effectiveness
(through the modulation of macromolecular complexes
bound to the ERa). An attractive possibility would thus
reside in not only blocking indirect ERa functions
which rely on MEK/ERK and PI3K pathways in SERM
resistant tumors, but to increase ERa translocation into
the nucleus.
The crystal structure of ERa bound to different
ligands has revealed a spectrum of conformational states
[9,42-44] that involve the repositioning of helix H12 of
the receptor’s ligand binding domain and formation the
receptor’s cofactor associating surfaces. It was proposed
that the ligand binding cavity has a remarkable plasticity
with a preferential binding mode for distal hydroxyl
groups [43] showing similar orientations for distal side
chains in a or b positions of different ligands [43].
RU39 and RU58 are derivatives of 17b-estradiol but
with different side chains. The shorter dimethyl-amino-
ethoxy-phenyl side chain is similar to the one in 4-
hydroxytamoxifen and likely to be easily accommodated
by the cavity (Mazaheri et al in preparation). In contrast,
RU58 has a bulky hydrophobic side chain similar to the
one in fulvestrant (ICI) which hampers the folding of
helix 12. Thus the molecular structure of ERa ligands
alone indicates the potential for SERM or SERD -like
activities of the compound (Mazaheri et al. in
preparation).
Interestingly, E2 induced focal accumulations of ERa
scattered throughout the nucleus in the presence of E2
and of SERDs (Figure 3A and 4A, D). In agreement with
this observation, numerous ERa-rich domains of about
100 nm are detectable following E2 stimulation (data
not shown). It is well established that upon E2 addition,
ERa binds to promoter of ERa-target genes [45].
Stimulated genes are found at numerous sites in the
nucleus similarly to ERa protein [46]. Thus, we propose
that the observed ERa rich nuclear clusters correspond
to association of the receptor with chromatin structures
of ERa-responsive genes and the proteasome
(Figure 3Ae and 4B) to ensure its own turnover while tar-
get genes are being transcribed. Similarly, SERD-bound
ERa also concentrated into nuclear foci (Figure 3Ah, k and
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3B) which frequently colocalize with the proteasome inde-
pendently of DNA binding. This may explain why ligand
bound ERa is less dynamic, and appears more strongly
associated with nuclear matrix like structures [27].
Thus we propose a simple explanation reconciling all
previous observations of ERa dynamics: ligands that
allow ERa to bind its target sequence and to recruit
macromolecular complexes induce ERa nuclear degra-
dation or accumulation (E2 or SERMs); ligands that
bind to ERa but do not lead to DNA binding due to
conformational changes of the receptor do not induce
relocalization of the receptor, but accelerate its degrada-
tion (SERDs); finally, ligands that induce association of
ERa with the proteasome (E2 and SERDs) lead to focal
accumulations and immobilize the ERa. It is the asso-
ciation with the proteasome [47] and not active degrada-
tion by the proteasome that leads to ERa sequestration.
In the last 30 years clinical use of tamoxifen signifi-
cantly improved survival rates of patients with
hormone-dependent breast cancer types. However, resis-
tance to this therapy arises frequently and numerous
side effects exist. Since it is well established that total
ERa content correlates with tumor growth in response
to different ligands, it is crucial to characterize the exact
mechanisms involved in anti-estrogen action and the
impact of their structure on ERa conformation, co-
factor recruitment and cellular compartmentalization.
Knowledge of these parameters may allow to develop
new compounds useful for patients resistant to existing
therapies but may also benefit early diagnostics and
treatment design.
Conclusions
In conclusion the results of this study indicate the
impact of the estradiol and several SERM and SERD
compounds, in particular RU39,411 and RU58,668, on
nucleocytoplasmic shuttling and protein turnover of
estrogen receptor alpha (ERa) in human breast cancer
cell lines. We found that ligands directly affect the
nuclear fate and protein turnover of the receptor inde-
pendently of their impact on transcription.
Methods
Reagents
17b-estradiol (E2), 4-hydroxytamoxifen (OHT) and Lep-
tomycine B (LMB) were purchased from Sigma-Aldrich
(St. Louis, MO). ICI 182,780 (ICI) was purchased from
Zeneca Pharmaceuticals. RU39,411 (RU39) and
RU58,668 (RU58) were kindly provided by Dr. J.M.
Renoir (Paris, France). Stock solutions of E2, OHT, ICI,
RU39 and RU58 were prepared in ethanol. Stock solu-
tion of LMB was prepared in methanol. The solution of
proteasome inhibitor acetyl-leucyl-leucyl-norleucinal
(ALLN) was purchased from Calbiochem.
Rabbit polyclonal anti-ERa (HC-20), rabbit polyclonal
anti-lamin A (H-102), rabbit polyclonal anti-cytokeratine
18 (H-80) were purchased from Santa Cruz Biotechnol-
ogy, Inc. Mouse monoclonal anti-GAPDH (MAB374)
was purchased from Chemicon International, mouse
monoclonal anti-GFP from Roche, mouse monoclonal
anti-a-tubulin (clone DM1A) from Sigma-Aldrich.
Mouse monoclonal anti-20S proteasome subunit a2
(clone MCP21) was gift from Dr. M.P. Bousquet (IPBS,
Toulouse, France).
All cell culture products were obtained from
Invitrogen.
Cell culture and generation of stable GFP-ERa cell line
Human breast cancer cell lines were maintained in Dul-
becco’s modified Eagle’s medium F-12 (DMEM F-12)
with Glutamax containing 50 μg/ml gentamicin, 1 mM
sodium pyruvate and 10% heat-inactivated fetal calf
serum. All cells were grown at 37°C in a humidified
atmosphere containing 5% CO2. The stably transfected
GFP-ERa reporter SK19 cell line was generated from
ERa-positive breast cancer MCF-7 cells (ATCC). 2nd
passage cells were transfected with a GFP-ERa expres-
sion vector (pEGFP-C2-hERa) using FuGENE® HB
Transfection Reagent (Roche Applied Science) and
G418 resistant clones were selected at the concentration
1 mg/ml. GFP-ERa expressing clones were isolated, ERa
protein expression in response to estradiol and to anti-
estrogens was quantified using fluorescence microscopy
and western blot. Expression of ERa-regulated genes
was tested by qRT-PCR and compared to gene-expres-
sion regulation in MCF-7 cells. The clone SK19 in
which GFP-ERa behavior was comparable to endogen-
ous ERa was selected for further investigation.
To study the effects of estrogens and antiestrogens,
cells were grown for 3 days in medium containing phe-
nol red-free DMEM F-12 supplemented with 5% char-
coal-stripped fetal calf serum, without gentamicin and
sodium pyruvate. Cells were subsequently treated or not
with 10 nM E2, 1 μM ICI, 1 μM OHT, 1 μM RU39,
1 μM RU58 for the indicated times. To study ERa
degradation by the proteasome, cells were pre-treated
30 min with 100 μM ALLN, a proteasome inhibitor, or
10 nM LMB, a nuclear export inhibitor.
Cell extracts and Western blots
MCF-7 cells grown in 6-well plates were treated as indi-
cated, washed with ice-cold PBS and collected by centri-
fugation. Total cell lysates were prepared by
resuspension of cells in 100 μl lysis buffer (50 mM Tris
pH = 6.8, 2% SDS, 5% glycerol, 2 mM EDTA, 1.25%
b-mercaptoethanol, 0.004% Bromophenol blue). The
samples were boiled for 20 min at 95°C and cleared by
centrifugation at 12 000 × g for 10 min. Protein
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concentration was determined by an Amido Schwartz
assay when the samples contained SDS. Samples were
subjected to SDS-PAGE and proteins transferred onto
nitrocellulose membranes. Western blot analysis was
performed as previously described [48] using ERa and
GAPDH antibodies and quantified using the TINA PC-
Base Software from FUJI.
qRT-PCR experiments
Total RNAs were extracted using TRIzol reagent (Invi-
trogen) following the manufacturer’s protocol. 1-5 μg of
total RNA was reverse transcribed in a final volume of
20 μl using SuperScript™III Reverse Transcriptase (Invi-
trogen). cDNA was stored at -80°C. All target transcripts
were detected using quantitative RT-PCR (SYBRGreen
SuperMix, Invitrogen) assays on a Mastercycler Realplex
device (Eppendorf) using TBP or RPLP0 genes as endo-
genous control for normalization of the data. The fol-














The results were analyzed using Mastercycler Realplex
and qBASE software.
Cell fractionation
Three hours after incubation with ERa ligands, SK19
cells were washed with ice-cold PBS, scraped and centri-
fuged at 1,500 rpm for 5 min at 4°C. The pellets were
resuspended in 150 μl digitonin lysis buffer containing
1% digitonin and 1 mM EDTA in PBS, immediately cen-
trifuged at 13,000 rpm for 20 min at 4°C, to obtain the
cytosolic fraction (C). The pellets were resuspended in
150 μl HEPES lysis buffer containing 1% Triton X-100,
10% glycerol, 10 μg/ml leupeptin, 5 μg/ml aprotinin,
1 mM PMSF, 1 mM Na3VO4 and 50 mM NaF in
HEPES buffer (25 mM HEPES, 0.3 M NaCl, 1.5 mM
MgCl2, 20 mM b-glycerol-phosphate, 2 mM EDTA,
2 mM EGTA and 1 mM DTT), kept 15 min on ice and
centrifuged at 13,000 rpm for 15 min at 4°C, to obtain
the soluble nuclear fraction (SN). The pellets from the
previous step were resuspended in 100 μl of a third buf-
fer containing 95% Laemmli buffer and 5% b-mercap-
toethanol and incubated 5 min on ice and boiled for
20 min at 95°C to obtain the insoluble nuclear fraction
(IN). The different fractions were stored at -80°C until
use. Protein concentrations were determined using the
Bio-Rad Protein Assay (Bio-Rad).
Immunofluorescence and Fluorescence microscopy
For indirect immunofluorescence experiments, SK19
cells were grown for 3 days on coverslips in DMEM
without phenol red, containing 5% charcoal-stripped
fetal serum. After 3 days, cells were treated for 1 h with
the following ligands: 10 nM E2, 1 μM ICI, 1 μM OHT,
1 μM RU39, 1 μM RU58. Cells were then washed twice
with PBS, fixed in 4% paraformaldehyde/PBS for 10 min
at room temperature, subsequently permeabilized with
0.5% Triton X-100 in PBS for 15 min at room tempera-
ture, counterstained with DAPI (4’,6-diamidino-2-pheny-
lindole) and mounted on microscopy slides.
To study co-localization of ERa and proteasome by
immunofluorescence, SK19 cells were grown for 3 days
on coverslips in DMEM without phenol red, containing
5% charcoal-stripped fetal serum and next treated for
3 h with drugs as indicated above. To block protea-
some-mediated ERa degradation, the cells were incu-
bated 30 min with 100 μM ALLN prior to treatment
with ICI or RU58. Before immunostaining, cells were
fixed in 4% paraformaldehyde/PBS for 30 minutes at
room temperature, washed three times in PBS,
quenched in 75 mM NH4Cl containing 20 mM glycine
and permeabilized with 0.5% Triton X-100 in PBS for
30 minutes. Next, cells were washed with PBS, blocked
for 1 h at room temperature in 5% dry milk in TBS-T
(20 mM TRIS-HCl, 150 mM NaCl, 0.1% Tween 20, pH
= 7.4) and incubated overnight at 4°C with anti-20S pro-
teasome antibody at a final concentration 2 μg/ml in 5%
dry milk in TBS-T followed, after washing, by incuba-
tion with the Alexa Fluor® 647 goat anti-mouse second-
ary antibody (1:1000, Invitrogen, Molecular Probes) for
90 min in the dark at room temperature. Finally, cells
were washed with TBS-T, counterstained with DAPI
and mounted on microscopy slides.
Cells were examined by fluorescence microscopy using
an Olympus IX-81 microscope, equipped with a Cool-
SNAP HQ camera (Roper Scientific) and imaged
through an Olympus oil-immersion objective 100x PLA-
NAPO NA1.4. Images were recorded and deconvolved
using Metamorph software (Universal Imaging). All
images were processed for presentation using Adobe
Photoshop 9.0.2.
Electron microscopy
MCF-7 cells were grown and treated as described above.
For immune-electron microscopy cells were fixed with
4% paraformaldehyde in Na cacodylate buffer (pH 7.4),
dehydrated in a graded series of ethanol and embedded
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in acrylic resin (LRWhite). 80 nm ultrathin sections
were mounted on Nickel grids, incubated with 2% BSA/
PBS and incubated overnight at 4°C with a mixture of
primary antibodies (anti -20S proteasome antibody at
final concentration 2 μg/ml and anti-ERa antibody
(dilution 1/500)) in 2% BSA/PBS, washed 5 times for
5 mins in 1% BSA/PBS and then labeled for 1 h with
6 nm goat anti-mouse and 10 nm goat anti-rabbit gold
conjugated particles in 1% BSA/PBS. Grids were finally
washed 4 times for 5 mins in 1% BSA/PBS, incubated
for 15 mins in 1% glutaraldehyde/PBS, washed 2 times
for 5 mins in PBS, 3 times in distilled water and dried
at room temperature. The samples were visualized using
120 kV Jeol electron microscope at 80 kV and images
were captured using a digital camera AMT.
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